Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade

Keros Therapeutics’ ambitions to go up against Merck & Co’s Winrevair with its investigational pulmonary arterial hypertension therapy, cibotercept, have taken a knock after safety concerns halted enrolment in two treatment arms of its Phase II trial. The move was triggered by unexpected cases of pericardial effusion with the drug at its higher doses, prompting a 73% decline in its share price on NASDAQ on 12 December, and leaving it trading at around cash at $18.43.

Keros’s path forward is far from clear, but some analysts say that there is still some hope for the product as well as value in the firm’s wider pipeline, making...